3-Acetyl-4-iso-propoxybenzoic Acid | 252901-49-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-Acetyl-4-iso-propoxybenzoic Acid
• 英文别名: 3-acetyl-4-iso-propyloxybenzoic acid；3-Acetyl-4-isopropoxybenzoic acid；3-acetyl-4-propan-2-yloxybenzoic acid
• CAS: 252901-49-8
• 化学式: C₁₂H₁₄O₄
• 分子量: 222.241
• InChiKey: BUIHXCCPDBHYJZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  63.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-Acetyl-4-iso-propoxybenzoic Acid 生成 (+/-)-3-Acetyl-N-(1,2,3,5,6,10b-hexahydropyrrolo[2,1-a]isoquinolin-9-yl)-4-isopropoxybenzamide hydrochloride
  参考文献：
  名称：

  TRICYCLIC CARBOXAMIDES

  摘要：

  公开号：

  EP1102769B1

文献信息

• Novel compounds
  申请人：SmithKline Beecham p.l.c.

  公开号：US20030036551A1

  公开（公告）日：2003-02-20

  1 Compounds of formula (I) wherein Q is a monocyclic or bicyclic aryl or heteroaryl ring; R 1 is hydrogen; R 2 is hydrogen or up to three substituents selected from halogen, NO 2 , CN, N 3 , CF 3 O—, CF 3 S—, CF 3 SO 2 —, CF 3 CO—, C 1-6 alkyl, C 1-6 alkenyl, C 1-6 alkynyl, C 1-6 perfluoroalkyl, C 3-6 cycloalkyl, C 3-6 cycloalkyl-C 1-4 alkyl-, C 1-6 alkylO—C 1-6 alkylCO—, C 3-6 cycloalkylO—, C 3-6 cycloalkylCO—, C 3-6 cycloalkyl-C 1-4 alkylO—, C 3-6 cycloalkyl-C 1-4 alkylCO—, phenyl, phenoxy, benzyloxy, benzoyl, phenyl-C 1-4 alkyl-, C 1-6 alkylS—, C 1-6 alkylSO 2 —, (C 1-4 alkyl) 2 NSO 2 —,(C 1-4 alkyl)NHSO 2 —, (C 1-4 alkyl) 2 NCO—, (C 1-4 alkyl)NCHO—, or CONH 2 , or —NR 3 R 4 where R 3 is hydrogen or C 1-4 alkyl, and R 4 is hydrogen, C 1-4 alkyl, formyl, —CO 2 C 1-4 alkyl, or —COC 1-4 alkyl, or two R 2 groups together form a carbocyclic ring that is saturated or unsaturated and unsubstituted or substituted by —OH or ═O; X is halogen, C 1-6 alkoxy, C 1-6 alkyl, or C 1-6 perfluoroalkyl, and; Y is hydrogen, halogen, C 1-6 alkoxy, C 1-6 alkyl, or C 1-6 perfluoroalkyl; but excluding the compounds N-(5-Iodo-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-azidobenzamide and N-(5-iodo-1,2,3,4-tetrahydroiso-quinolin-7-yl)-5-benzoyl-2-methoxybenzamide; and pharmaceutically acceptable salts or solvates thereof possess anticonvulsant activity and are useful in the treatment of a variety of disorders.

  化合物的公式为（I），其中Q是单环或双环芳基或杂环芳基环；R1为氢；R2为氢或最多三个取自卤素、NO2、CN、N3、CF3O-、CF3S-、 O2-、CF3CO-、C1-6烷基、C1-6烯基、C1-6炔基、C1-6全氟烷基、C3-6环烷基、C3-6环烷基-C1-4烷基-、C1-6烷基O-C1-6烷基CO-、C3-6环烷基O-、C3-6环烷基CO-、C3-6环烷基-C1-4烷基O-、C3-6环烷基-C1-4烷基CO-、苯基、苯氧基、苄氧基、苯甲酰基、苯基-C1-4烷基-、C1-6烷基S-、C1-6烷基SO2-、（C1-4烷基）2NSO2-、（C1-4烷基）NHSO2-、（C1-4烷基）2NCO-、（C1-4烷基）NCHO-或CONH2，或—NR3R4，其中R3为氢或C1-4烷基，R4为氢、C1-4烷基、甲酰基、—CO2C1-4烷基或—COC1-4烷基，或两个R2基组成一个饱和或不饱和的碳环，未取代或被—OH或═O取代；X为卤素、C1-6烷氧基、C1-6烷基或C1-6全氟烷基；Y为氢、卤素、C1-6烷氧基、C1-6烷基或C1-6全氟烷基；但不包括N-(5-碘-1,2,3,4-四氢异喹啉-7-基)-4-叠氮苯甲酰胺和N-(5-碘-1,2,3,4-四氢异喹啉-7-基)-5-苯甲酰基-2-甲氧基苯甲酰胺；其药学上可接受的盐或溶剂化合物具有抗癫痫活性，并可用于治疗多种疾病。
• Tetrahydronaphthyridinyl-carboxamides having anti-convulsant activity
  申请人：SmithKline Beecham p.l.c.

  公开号：US20020143029A1

  公开（公告）日：2002-10-03

  Compounds of formula (I) and pharmaceutically acceptable salts and solvates: 1 where R 1 is hydrogen, C 1-6 alkyl (optionally substituted by hydroxy or C 1-4 alkoxy), phenyl-C 1-4 alkyl-, C 1-6 alkenyl, C 1-6 alkynyl; R 2 is hydrogen or up to three substituents selected from halogen, NO 2 , CN, N 3 , CF 3 O—, CF 3 S—, CF 3 CO—, C 1-6 alkyl, C 1-6 alkenyl, C 1-6 alkynyl, C 1-6 perfluoroalkyl, C 3-6 cycloalkyl, C 3-6 cycloalkyl-C 1-4 alkyl-, C 1-6 alkylO—, C 1-6 alkylCO—, C 3-6 cycloalkylO—, C 3-6 cycloalkylCO—, C 3-6 cycloalkyl-C 1-4 alkylO—, C 3-6 cycloalkyl-C 1-4 alkylCO—, phenyl, phenoxy, benzyloxy, benzoyl, phenyl-C 1-4 alkyl-, C 1-6 alkylS—, C 1-6 alkylSO 2 —, (C 1-4 alkyl) 2 NSO 2 —, (C 1-4 alkyl)NHSO 2 —, (C 1-4 alkyl) 2 NCO—, (C 1-4 alkyl)NHCO— or CONH 2 ; or —NR 5 R 6 where R 5 is hydrogen or C 1-4 alkyl, and R 6 is hydrogen, C 1-4 alkyl, formyl, —CO 2 C 1-4 alkyl or —COC 1-4 alkyl; or two R 2 groups together form a carbocyclic ring that is saturated or unsaturated. R 3 groups and R 4 groups are each independently hydrogen or C 1-6 alkyl and/or the two R 3 groups and/or the two R 4 groups together form a C 3-6 spiroalkyl group, provided that at least one R 3 or R 4 group is not hydrogen; and X is selected from hydrogen, halogen, cyano, alkyl and alkoxy. are useful in the treatment and prophylaxis of epilepsy, migraine, and other disorders.

  公式（I）化合物及其药学上可接受的盐和溶剂化合物：其中R1为氢、C1-6烷基（可选地被羟基或C1-4烷氧基取代）、苯基-C1-4烷基、C1-6烯基、C1-6炔基；R2为氢或最多三个取代基，所选自卤素、NO2、CN、N3、CF3O—、CF3S—、CF3CO—、C1-6烷基、C1-6烯基、C1-6炔基、C1-6全氟烷基、C3-6环烷基、C3-6环烷基-C1-4烷基、C1-6烷氧基、C1-6烷基CO—、C3-6环烷基烷氧基、C3-6环烷基CO—、C3-6环烷基-C1-4烷氧基、C3-6环烷基-C1-4烷基CO—、苯基、苯氧基、苄氧基、苯甲酰基、苯基-C1-4烷基、C1-6烷基S—、C1-6烷基SO2—、（C1-4烷基）2NSO2—、（C1-4烷基）NHSO2—、（C1-4烷基）2NCO—、（C1-4烷基）NHCO—或CONH2；或—NR5R6，其中R5为氢或C1-4烷基，R6为氢、C1-4烷基、甲酰基、—CO2C1-4烷基或—COC1-4烷基；或两个R2基共同形成一个饱和或不饱和的碳环。R3基和R4基各自独立地为氢或C1-6烷基，或两个R3基和/或两个R4基共同形成一个C3-6螺环烷基，前提是至少有一个R3或R4基不是氢；X选自氢、卤素、氰基、烷基和烷氧基。这些化合物对于治疗和预防癫痫、偏头痛和其他疾病是有用的。
• Isoquinolinyl carboxamides and their use as anticonvulsants
  申请人：SMITHKLINE BEECHAM PLC

  公开号：EP1367055A1

  公开（公告）日：2003-12-03

  Compounds of formula (I): wherein Q is a monocyclic or bicyclic aryl or heteroaryl ring; R1 is hydrogen; R2 is hydrogen or up to three substituents selected from halogen, NO2, CN, N3, CF3O-, CF3S-, CF3SO2-, CF3CO-, C1-6alkyl, C1-6alkenyl, C1-6alkynyl, C1-6perfluoroalkyl, C3-6cycloalkyl, C3-6cycloalkyl-C1-4alkyl-, C1-6alkylO-, C1-6alkylCO-, C3-6cycloalkylO-, C3-6cycloalkylCO-,C3-6cycloalkyl-C1-4alkylO-, C3-6cycloalkyl-C1-4alkylCO-, phenyl, phenoxy, benzyloxy, benzoyl, phenyl-C1-4alkyl-, C1-6alkylS-, C1-6alkylSO2-, (C1-4alkyl)2NSO2-, (C1-4alkyl)NHSO2-, (C1-4alkyl)2NCO-, (C1-4alkyl)NHCO-, or CONH2, or -NR3R4 where R3 is hydrogen or C1-4 alkyl, and R4 is hydrogen, C1-4alkyl, formyl, -CO2C1-4alkyl, or -COC1-4alkyl, or two R2 groups together form a carbocyclic ring that is saturated or unsaturated and unsubstituted or substituted by -OH or =O; X is halogen, C1-6 alkoxy, C1-6 alkyl, or C1-6 perfluoroalkyl, and; Y is hydrogen, halogen, C1-6 alkoxy, C1-6 alkyl, or C1-6 perfluoroalkyl; but excluding the compounds N-(5-Iodo-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-azidobenzamide and N-(5-iodo-1,2,3,4-tetrahydroisoquinolin-7-yl)-5-benzoyl-2-methoxybenzamide; and pharmaceutically acceptable salts or solvates thereof possess anticonvulsant activity and are useful in the treatment of a variety of disorders.

  式(I)化合物： 其中 Q 是单环或双环芳基或杂芳基环； R1 是氢 C1-6烷基CO-、C3-6环烷基O-、C3-6环烷基CO-、C3-6环烷基-C1-4烷基O-、C3-6环烷基-C1-4烷基CO-、苯基、苯氧基、苄氧基、苯甲酰基、苯基-C1-4烷基、C1-6烷基S-、C1-6烷基SO2-、(C1-4烷基)2NSO2-、 (C1-4烷基)NHSO2-，(C1-4烷基)2NCO-，(C1-4烷基)NHCO-，或 CONH2，或-NR3R4，其中 R3 是氢或 C1-4 烷基，R4 是氢、C1-4烷基、甲酰基、-C2C1-4烷基或-COC1-4烷基，或两个 R2 基团共同形成饱和或不饱和且未被取代或被-OH 或 =O 取代的碳环； X 是卤素、C1-6 烷氧基、C1-6 烷基或 C1-6 全氟烷基，以及 Y 是氢、卤素、C1-6 烷氧基、C1-6 烷基或 C1-6 全氟烷基； 但不包括化合物 N-(5-碘-1,2,3,4-四氢异喹啉-7-基)-4-叠氮苯甲酰胺和 N-(5-碘-1,2,3,4-四氢异喹啉-7-基)-5-苯甲酰基-2-甲氧基苯甲酰胺； 及其药学上可接受的盐或溶液具有抗惊厥活性，可用于治疗多种疾病。
• SUBSTITUTED ISOQUINOLINE DERIVATIVES AND THEIR USE AS ANTICONVULSANTS
  申请人：SmithKline Beecham plc

  公开号：EP1042296B1

  公开（公告）日：2004-02-25
• TETRAHYDRONAPHTHYRIDINYL-CARBOXAMIDES HAVING ANTI-CONVULSANT ACTIVITY
  申请人：SmithKline Beecham plc

  公开号：EP1084122B1

  公开（公告）日：2003-10-22